Articolul precedent |
Articolul urmator |
324 3 |
Ultima descărcare din IBN: 2023-12-08 19:55 |
SM ISO690:2012 MACARI, Doina, SCUTARI, Corina. Evaluation of the antibacterial consumption in public medical and sanitary institutions in the R. of Moldova in the COVID-19 pandemic. In: Cercetarea în biomedicină și sănătate: calitate, excelență și performanță, Ed. 1, 20-22 octombrie 2021, Chişinău. Chișinău, Republica Moldova: 2021, p. 427. ISBN 978-9975-82-223-7 (PDF).. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Cercetarea în biomedicină și sănătate: calitate, excelență și performanță 2021 | ||||||
Conferința "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță" 1, Chişinău, Moldova, 20-22 octombrie 2021 | ||||||
|
||||||
Pag. 427-427 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Despite the fact that antibiotics do not treat or prevent viral infections like COVID-19, the results of behavioural insight research conducted in 9 countries and areas of the European Region showed antibiotic use increasing throughout the pandemic along with cases. Objective of the study. The evaluation of the consumption of antibacterial preparations within the public medical institutions of the R. of Moldova in the COVID-19 pandemic, for the years 2019-2020 using the defined daily dose (DDD) as a unit of measurement. Material and Methods. Statistical data, results of centralized public procurement for 370-380 public medical institutions in the Republic of Moldova was analyzed according to the Center for Centralized Public Procurement in Health, using the unit of measurement of the defined daily dose (DDD). Results. As a result of the systematization of the data, there is a considerable increase for the following groups of antibacterial preparations: Glycopeptides, summary DDD for 2020 is 213823.25 (> 2522.37 %) compared to 2019), Macrolides, summary DDD for 2020 is 287882.19 (> 785.26 %) compared to 2019), there is also a significant increase for Carbapenems (>217.30 %), Sulfamides (>434.39%) and Polypeptides (> 197.86%). Some groups such as: Cephalosporins (>4.32 %), Amefnicoli (>25.70 %) increased insignificantly. At the same time, it should be mentioned that the use of preparations containing Chinolone (<18 %), Lincosamide (<29.54 %), Penicillins (<4.70 %) decreased. Conclusion. During the COVID-19 pandemic, the use of groups of antibacterial preparations (Glycopeptides, Macrolides, Carbapenems, Polypeptides) in the hospital sector increased excessively, which may cause an increase in long-term antibacterial resistance. |
||||||
Cuvinte-cheie Antibiotics, COVID-19, DDD, antibiotice, COVID-19, DDD |
||||||
|